智通财经网·2025-12-10 10:23Core Viewpoint - Fosun Pharma's subsidiary, Guilin Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of Foscarnet Sodium Injection, expanding its product line and addressing specific medical needs [1] Group 1: Product Approval - The approved indications for Foscarnet Sodium Injection include treatment for (1) cytomegalovirus retinitis in AIDS patients and (2) acyclovir-resistant mucocutaneous infections in immunocompromised patients [1] Group 2: Financial Investment - As of November 2025, the total R&D investment for this drug by the group is approximately RMB 4.98 million (unaudited) [1] Group 3: Market Potential - According to IQVIA CHPA data, the sales revenue for Foscarnet Sodium Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 86.4 million in 2024 [1]